Defence Therapeutics Inc. (DTC.CN)

1.1900 -0.0300 (-2.46%) At close: 03:59PM EDT

Defence Therapeutics Inc.

1680 – 200 Burrard Street
Vancouver, BC V6C 3L6
Canada
514 947 2272
https://defencetherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Sebastien Plouffe	CEO, President & Director	112.5k	N/A	1972
Mr. Patrick Joseph Meagher C.A., CPA, CA, CPA	CFO & Director	79.5k	N/A	1986
Dr. Moutih Rafei Ph.D.	Chief Scientific Officer & Director	12.5k	N/A	1982
Dr. Simon Beaudoin	Chief Technical Science Officer	N/A	N/A	1985
Ms. Carrie Cesarone	Corporate Secretary	N/A	N/A	1965

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

Defence Therapeutics Inc. engages in development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on development of vaccine for infectious disease and virus utilizing the ACCUMTM platform for drug delivery and effective treatments. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.

Corporate Governance

Defence Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.